| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4353 | 2018 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3086 | 2019 |
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial CN Sternberg, ID Davis, J Mardiak, C Szczylik, E Lee, J Wagstaff, ... Journal of clinical oncology 28 (6), 1061-1068, 2010 | 3077 | 2010 |
| Making antibodies by phage display technology G Winter, AD Griffiths, RE Hawkins, HR Hoogenboom Annual review of immunology 12 (1), 433-455, 1994 | 2615 | 1994 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2156 | 2013 |
| Selection of phage antibodies by binding affinity: mimicking affinity maturation RE Hawkins, SJ Russell, G Winter Journal of molecular biology 226 (3), 889-896, 1992 | 1052 | 1992 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 976 | 2012 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 974 | 2019 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 763 | 2019 |
| Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours JK Ramage, AHG Davies, J Ardill, N Bax, M Caplin, A Grossman, ... Gut 54 (suppl 4), iv1-iv16, 2005 | 714 | 2005 |
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update CN Sternberg, RE Hawkins, J Wagstaff, P Salman, J Mardiak, CH Barrios, ... European journal of cancer 49 (6), 1287-1296, 2013 | 520 | 2013 |
| Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ... Journal of Clinical Oncology 32 (14), 1412-1418, 2014 | 493 | 2014 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 447 | 2016 |
| The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens RD Guest, RE Hawkins, N Kirillova, EJ Cheadle, J Arnold, A O'Neill, ... Journal of immunotherapy 28 (3), 203-211, 2005 | 439 | 2005 |
| The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent … FC Thistlethwaite, DE Gilham, RD Guest, DG Rothwell, M Pillai, DJ Burt, ... Cancer Immunology, Immunotherapy 66, 1425-1436, 2017 | 378 | 2017 |
| Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial SR Bramhall, MT Hallissey, J Whiting, J Scholefield, G Tierney, RC Stuart, ... British journal of cancer 86 (12), 1864-1870, 2002 | 369 | 2002 |
| Retroviral vectors displaying functional antibody fragments SJ Russell, RE Hawkins, G Winter Nucleic acids research 21 (5), 1081-1085, 1993 | 363 | 1993 |
| Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library RHJ Begent, MJ Verhaar, KA Chester, JL Casey, AJ Green, MP Napier, ... Nature Medicine 2 (9), 979-984, 1996 | 353 | 1996 |
| The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 … JS Bridgeman, RE Hawkins, S Bagley, M Blaylock, M Holland, DE Gilham The Journal of Immunology 184 (12), 6938-6949, 2010 | 350 | 2010 |
| Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma C Ralph, E Elkord, DJ Burt, JF O'Dwyer, EB Austin, PL Stern, RE Hawkins, ... Clinical Cancer Research 16 (5), 1662-1672, 2010 | 302 | 2010 |
